Peptide-Drug Conjugates in Targeted Cancer Therapy

Peptide-drug conjugates (PDCs) represent a versatile class of targeted therapeutics in oncology, combining the selectivity of tumour-homing peptides with potent cytotoxic agents via customised linker chemistries. By exploiting peptides that bind specific cell-surface receptors overexpressed on malignant cells, PDCs enhance the accumulation of cytotoxins within tumour microenvironments while sparing healthy tissues, thereby improving therapeutic indices and reducing systemic toxicity. Design of a PDC encompasses three modular components: a targeting peptide, a cleavable or biodegradable linker, and a bioactive payload. Advances in peptide engineering have addressed classical limitations of rapid proteolysis and short circulation half-life through cyclisation, incorporation of non-natural amino acids and conjugation to nanoparticles or polymer scaffolds. Emerging clinical-stage constructs, including bicyclic toxin conjugates and peptide-dendrimer assemblies, exemplify the translational potential of this approach. Current challenges centre on optimising receptor specificity, ensuring controlled intracellular release of the drug, and balancing manufacturing complexity with regulatory requirements. Globally, PDCs are poised to complement or succeed antibody-drug conjugates in settings where deep tissue penetration, rapid tumour uptake and minimised immunogenicity are critical.

Research from Nature Portfolio

Recent studies have delivered a refined peptide selection platform to identify high-affinity ligands for key oncogenic receptors. One notable investigation applied peptide array–cell binding assays to a library of epidermal growth factor receptor (EGFR)-targeting analogues, uncovering a novel peptide that exhibits several-fold enhanced uptake in triple-negative breast cancer cells compared with the canonical GE11 ligand. This analogue demonstrated dose-dependent, saturable internalisation at low micromolar concentrations and full competition by native EGF, confirming receptor specificity. Such optimised peptides may be directly conjugated to cytotoxic drugs or formulated with nanocarriers to potentiate chemotherapy in receptor-driven tumours.

Peptide-Drug Conjugates in Targeted Cancer Therapy publication trend

The graph below shows the total number of articles in peptide-drug conjugates in targeted cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Peptide-drug conjugate (PDC): A molecular construct comprising a tumour-homing peptide linked to a cytotoxic or diagnostic payload.

Targeting peptide: A short amino acid sequence that binds selectively to cell-surface receptors overexpressed on cancer cells.

Linker: A chemical or biodegradable spacer that connects the peptide and drug, engineered to release the payload under specific physiological conditions.

Cytotoxic payload: The drug moiety in a PDC that induces cell death, which may include chemotherapeutics, radionuclides or novel toxin peptides.

Receptor-mediated endocytosis: The cellular uptake mechanism by which ligand-bound receptors internalise into endosomes, enabling intracellular delivery of conjugated drugs.

References

1. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells. Scientific Reports (2019).
2. Peptides as multifunctional players in cancer therapy. Experimental & Molecular Medicine (2023).
3. Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs). Chemical Society Reviews (2021).